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Abstract
Background: IL-33 is a recently characterized IL-1 family cytokine and found to be expressed in inflammatory diseases,
including severe asthma and inflammatory bowl disease. Recombinant IL-33 has been shown to enhance Th2-associated
immune responses and potently increase mast cell proliferation and cytokine production. While IL-33 is constitutively
expressed in endothelial and epithelial cells, where it may function as a transcriptional regulator, cellular sources of IL-33
and its role in inflammation remain unclear.
Methodology/Principal Findings: Here, we identify mast cells as IL-33 producing cells. IgE/antigen activation of bone
marrow-derived mast cells or a murine mast cell line (MC/9) significantly enhanced IL-33. Conversely, recombinant IL-33
directly activated mast cells to produce several cytokines including IL-4, IL-5 and IL-6 but not IL-33. We show that expression
of IL-33 in response to IgE-activation required calcium and that ionomycin was sufficient to induce IL-33. In vivo, peritoneal
mast cells expressed IL-33 and IL-33 levels were significantly lower within the skin of mast cell deficient mice, compared to
littermate controls. Local activation of mast cells promotes edema, followed by the recruitment of inflammatory cells. We
demonstrate using passive cutaneous anaphylaxis, a mast cell-dependent model, that deficiency in ST2 or antibody
blockage of ST2 or IL-33 ablated the late phase inflammatory response but that the immediate phase response was
unaffected. IL-33 levels in the skin were significantly elevated only during the late phase.
Conclusions/Significance: Our findings demonstrate that mast cells produce IL-33 after IgE-mediated activation and that
the IL-33/ST2 pathway is critical for the progression of IgE-dependent inflammation.
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Introduction
Mast cells are important in both innate and adaptive responses
and best characterized for their roles in defense against invading
pathogens and hypersensitivity responses. Activation of mast cells
leads to the release of potent inflammatory mediators, including
preformed mediators (e.g. histamine), lipid metabolites (e.g.
prostaglandins) and a plethora of cytokines and chemokines [1].
Mast cells can also be activated by a variety of stimuli and release
distinct patterns of mediators, depending on the type and strength
of stimuli [2]. The most characterized pathway to mast cell
activation is antigen-mediated crosslinking of IgE molecules that
bind via FceRI [3], that is highly expressed on mast cells and
important in allergic diseases.
Interleukin-33 (IL-1F11, NF-HEV) is a newly characterized
cytokine belonging to the IL-1 cytokine family that also includes
IL-1a, IL-1b, IL-1Ra (IL-1 receptor antagonist) and IL-18 [4]. It
contains an N-terminal predicted helix-turn-helix (HTH) motif
responsible for nuclear translocation and chromatin binding [5]
and an IL-1-like C-terminal domain. Full-length IL-33 is about
30 kDa and early data suggested that IL-33 required cleavage by
caspase-1 at Ser111 to be biologically active (about 18 kDa) [4].
However, more recent studies have defined that full-length IL-33
is biologically active [6,7,8]. While Schmitz et al. proposed that the
cleavage site for activation was at Ser111 [4], Cayrol and Girard
have more recently demonstrated cleavage within the IL-1-like C-
terminal domain at Asp178 that inactivates IL-33 [6].
IL-33 exerts its function by binding on its receptor ST2 (T1/
ST2, Fit-1, DER4), in associated with IL-1AcP and, in several
studies utilizing a recombinant 18 kD IL-33 molecule (represent-
ing the predicted Ser111 cleaved product (aa109-266 for mouse,
aa112-270 for human)), has been shown to modulate parasite
expulsion [9], pain sensitivity to antigen stimulation [10],
experimentally induced atherosclerosis [11], induce cutaneous
fibrosis [12], promote recruitment of Th2 cells, basophils and
eosinophils [13,14], as well as potently induce the activation and
survival of mast cells, independently of FceRI [15,16,17]. It also
enhances atypical Th2 response by promoting IL-5 and IL-13
production by T cells [18]. Recent data has also shown that in vivo
administration of IL-33109–266 can enhance IgE-driven anaphy-
lactic shock [19].
Despite thiswealth ofdata,demonstrating exogenous IL-33109–266
as an inflammatory regulator, the sources and functions of IL-
33 in vivo remain less characterized. This is despite mounting
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including severe asthma [20], allergic conjunctivitis [21] and
inflammatory bowel disease [22]. IL-33 protein is expressed by
high endothelial venule cells, in which it functions as a
transcriptional regulator [5], much like IL-1a and IL-18 have
been shown to do [23,24], and has also been found within the
nucleus of epithelial cells [25]. The initial profiling of organs or
cells for IL-33 mRNA demonstrated expression in purified
dendritic cells, epithelial cells, activated macrophages and,
interestingly, high expression in stomach, lung, brain and skin
tissues [4], all sites that are rich in mast cells. Additionally,
adipocytes have also been shown to express mRNA for IL-33 [26]
however their ability to produce IL-33 protein is unknown. This
may be an important consideration since skin fibroblasts, which
were initially shown to express IL-33 mRNA [4], have since been
shown to have no detectable IL-33 protein [25]. A recent report
showed that IL-33 can be expressed and released by activated
macrophages independent on caspase-1, -8 and calpain [27].
However, the specific sources of IL-33 protein during Th2-type
inflammation remain poorly defined.
We hypothesized that mast cells might be a source of IL-33 due
to their importance in a diverse range of inflammatory responses,
and particularly Th2-type immunity. Mast cells also express the
IL-33-related family members IL-1b and IL-18 upon their
activation [28,29]. However, unlike IL-1b and IL-18, IL-33
specifically promotes Th2-associated responses [4,30], which mast
cell activation has also been shown to do [31]. The results
presented here demonstrate that mast cells produce IL-33 and that
IgE-mediated activation potently enhances expression, both in
vitro and in vivo. Interestingly, IL-33 fails to induce its own
expression and we show a requirement for calcium-mediated
processes in IL-33 expression. Functionally, we demonstrate that
the IL-33/ST2 axis is important for the late phase response in a
mast cell-dependent model of anaphylaxis by recruiting of
inflammatory cells into the site of mast cell activation. Therefore,
our study defines IL-33 as an important mediator in regulating the
events between IgE-mediated mast cell triggering and the
development of subsequent inflammatory responses.
Materials and Methods
Reagents
Rabbit polyclonal anti-mouse IL-33 and recombinant IL-
33109–266 were obtained from Axxora. Mouse IgE (SPE-7 clone),
dinitrophenyl (DNP)-human serum albumin (DNP-HSA) and
ionomycin were obtained from Sigma. Murine IL-33 Quantikine
ELISA kit, rat monoclonal anti-mouse IL-33, rat IgG2a isotype,
goat anti-mouse ST2 for PCA model, goat IgG isotype and mouse
ST2/IL-1 R4 DouSet ELISA were from R&D Systems. Taqman
gene expression primers and probes were obtained from Applied
Biosystems. Murine OVA-specific IgE was produced from the
TOe hybridoma, as previously described [32]. Anti-CD16/32
(2.4G2), anti-CD117 (c-kit), anti-FceRI (MAR-1) were obtained
from BD Biosciences. Rat anti-mouse ST2 for flow cytometry was
obtained from MDBiosciences.
Animals
BALB/c and C57BL/6 female mice (4–6 weeks) were obtained
from Taconic Farms. WBB6F1/J-Kit
w/Kit
Wv (W/Wv) mice and
wildtype littermates (4–6 weeks) were obtained from Jackson Labs.
ST2 deficient mice were generated as previously described [33] and
obtained from Dr Andrew McKenzie at the MRC Laboratory of
Molecular Biology, Cambridge. Mast cell reconstitution of W/Wv
mice was performed by injection of 1610
7 BMMC and determined
by toluidine blue staining of tissues after 12 weeks while hematocrits
were performed to confirm no influence on anemia.
Ethics Statement
All animal studies were performed under the strict guidelines for
care and welfare set out by IACUC and in accordance with animal
protocol ID 2007-1260, which has been reviewed and approved
by the Northwestern University Animal Care and Use Committee.
Mast cell cultures
Bone marrow-derived mast cells (BMMC) were obtained by
flushing bone marrow from femurs using complete RPMI media,
10% FBS, penicillin/streptomycin and L-glutamine. Cells were
then cultured in mast cell growth media (complete RPMI media
+30 ng/ml recombinant mouse IL-3) for 5 weeks. Mast cell
phenotype was determined by toluidine blue straining (.96%) and
flow cytometry for double stained c-kit
+/IgE binding
+ cells
(.95%). MC/9 cells were obtained via the American Tissue
Culture Collection and maintained in mast cell growth media.
Gene Expression Analysis
Expression of mRNA for murine IL-4, IL-5, IL-6, IL-33 and
ST2 were determined using commercially available FAM-labeled
Taqman primers and probes (Applied Biosystems) on cDNA
derived from mRNA extracted using a Qiagen RNeasy mRNA
isolation kit. Gene expression was determined based on the delta
CT values between gene of interest and b-actin and compared to
the mean delta CT values for the control group to determine a fold
induction value, as previously described [34].
Flow cytometry
For intracellular staining of IL-33, unprimed or IgE primed
BMMC cells were stimulated for 24 hours with 1 mM ionomycin
or 0.5 mg/ml DNP-HSA in mast cell growth media. Peritoneal
cells were harvested by lavage of the peritoneal cavity with PBS.
Cells were blocked with anti-CD16/32 and permeabilized using
BD Cytoperm/wash (BD Pharmingen). Cells were stained for
1 hour using anti-IL-33 (2 mg/10
6 cells), followed by anti-rabbit
PE-labeled secondary antibody. Peritoneal cells were also stained
with CD117 (c-kit) and FceRI to enable identification of mast cells.
For surface staining of ST2, unprimed or IgE primed BMMC cells
were stimulated for 6 hours with or without 0.5 ug/ml DNP-HSA
in mast cell growth media. Cells were blocked with anti-CD16/32
and stained for 1 hour using rat monoclonal anti-ST2 (1 mg/10
6
cells), followed by anti-rat FITC-labeled secondary antibody.
Western Blot
Unprimed or IgE primed BMMC cells were stimulated for
24 hours with 0.5 mg/ml DNP-HSA in mast cell growth media.
Cells were lysed under sonication and 100 mg of total protein,
determined by Bradford Assay (Bio-Rad), was separated by 10%
SDS-PAGE and transferred to nitrocellulose membrane. Mem-
branes were probed with polyclonal rabbit anti-mouse IL-33
(1:2000). Membranes were stripped and reprobed for b-actin to
confirm equal loading.
Tissue Cytokine Quantification
Ear skin was homogenized in phosphate buffered saline (PBS)
containing 1:100 dilution of protease inhibitor cocktail (Sigma)
and the supernatant collected. The quantity of IL-33 in the
supernatant was determined using a murine IL-33 Quantikine
ELISA (R&D Systems) and normalized to the total protein content
of each sample, determined by BCA assay (Invitrogen).
Mast Cells Produce IL-33
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Immunohistochemistry
PCA was performed as previously described [35] using
intradermal anti-DNP IgE (100 ng) (SPE-7 clone, Sigma) and
intravenous DNP-HSA (100 mg). Where indicated, anti-ST2 or
IL-33 was administrated 1 hour before DNP-HSA challenge. The
thickness of ears was measured at the indicated time points. In
some experiments, ear tissue was collected 24 hours after
intravenous challenge, frozen and embedded in OCT compound.
7 mm sections were cut and fixed with ice cold 1:1 acetone/
methanol before staining using a DAB- immunohistochemistry
detection kit (R&D systems), as per the manufactures instructions.
Rabbit polyclonal anti-IL-33 (Axxora) (1:500) was used as a
primary detection antibody and biotinylated goat anti-rabbit IgG
(Zymed) was used as a secondary antibody. After staining, sections
were counterstained with Mayer’s hematoxylin. Images were
generated using a Leica spinning-disc confocal microscope and
Spot-image analysis software.
Results
Bone Marrow-derived Mast Cells Express IL-33 Upon IgE-
driven Activation
We initially investigated if mast cells could also produce IL-33.
Utilizing DNP-specific IgE primed BMMC, we show that IL-33
mRNA was upregulated within 30 minutes of stimulation and
peaked at 4 hours after antigen-driven activation with DNP-HSA
(Figure 1A). While IL-1b and IL-18 were also increased (data not
shown), the expression of IL-33 was more than ten fold higher
than either of these related cytokines. This was antigen specific,
since DNP-HSA stimulated expression of IL-33 in mast cells
primed with DNP-specific IgE but not OVA-specific IgE while
concomitantly, OVA induced expression in these cells (Figure 1B).
In addition, we determined whether IL-33 protein could be
detected within mast cells by flow cytometry. We found that IL-33
protein was detectable in unstimulated cells and enhanced in IgE/
DNP stimulated cells (Figure 1C). We then investigated if mast
Figure 1. In vitro mast cells produce IL-33 upon specific activation by IgE. 1610
6 BMMC were primed with 1 mg/ml anti-DNP IgE (SPE-7
clone) overnight and stimulated by addition of 0.5 mg/ml DNP-HSA (black bars) or vehicle control (white bars). After the indicated times, gene
expression of mouse IL-33 was determined by real-time RT-PCR (A). Either anti-DNP IgE or anti-OVA IgE was used in combination with either DNP-HSA
or OVA, as indicated, and IL-33 gene expression determined (B). Intracellular staining for IL-33 was determined in permeabilized BMMC 24 hours after
stimulation of 0.5 mg/ml DNP-HSA (C). Western blot analysis of BMMC lysate from stimulated or unstimulated cells 24 hours after stimulation (D).
Recombinant, mouse IL-33109–266 was used as a positive control. Data represents 3 independent experiments. Primary mast cells were obtained by
peritoneal lavage, identified as CD117
+/FceRI
+ and intracellular staining for IL-33 performed after permeabilization (E). Data represents 2 independent
experiments.
doi:10.1371/journal.pone.0011944.g001
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IL-33 protein were detected in unstimulated cells at a full-length
size of 31 kD and IgE-mediated stimulation upregulated this form,
with no evidence of cleavage products (Figure 1D). Quantification
of three independent experiments demonstrated a significant
increase in the relative band intensity of the IL-33 protein
(8586121 in unstimulated cells to 13936250 in stimulated cells).
ATP addition (10–500 mM), which has been demonstrated to
promote caspase-1-activated IL-1b secretion [36], was insufficient
to induce secretion of IL-33 (data not shown), supporting the lack
of a caspase-1 mediated release mechanism for IL-33, while LPS
(5–100 ng/ml), shown to promote release of IL-6 and TNFa from
BMMC [37], had no effect on release either with or without
concurrent IgE-mediated stimulation (data not shown). Finally, we
utilized intracellular staining to investigate if primary mast cells
also expressed IL-33. Peritoneal lavage was performed and the
recovered cells contained a distinct population of CD117
+/FceRI
+
mast cells that stained positive for IL-33 (Figure 1E).
IL-33 expression by mast cells is dependent on calcium
and not induced by IL-33
We further explored the regulation of IL-33 expression in mast
cells. IL-33 itself has been shown to be a potent inducer of mast
cell cytokine production [15,16,17,38], independent of FceRI
signaling. We postulated that released IL-33 might promote its
own expression by activating mast cells, in a potentially autocrine
fashion. To test this, we compared the expression of cytokine genes
in response to IgE/FceRI activation or to IL-33 activation. The
expression of IL-4, IL-5, IL-6 and IL-33 were induced in BMMC
(Figure 2A) after either stimulation. However, IL-33 was uniquely
stimulated by IgE-mediated activation and not by IL-33. Similar
results were obtained using MC/9 cells, a murine mast cell line
(Figure 2B). We next compared the signaling pathways from
FceRI and ST2. The pathways for IgE-mediated FceRI activation
are well characterized and calcium-mediated activation is vital for
many downstream events [3]. Conversely, IL-33 mediated
activation via ST2 and the IL-1 receptor accessory protein (IL-
1RAcP) activates ERK, JNK, p38, IkB and NF-kB [4,39].
Therefore, we investigated the role of calcium processes in the
expression of IL-33 in mast cells. Ionomycin (0.25–1 mM)
treatment of BMMC was sufficient to induce robust, dose-
dependent expression of IL-33 (Figure 2C) as well as protein
expression by intracellular staining (data not shown). As shown in
Figure 2D, ionomycin-induced IL-33 could be suppressed by
addition of EDTA (5 mM) into the culture media. Similarly,
EDTA suppressed the expression of IL-33 by IgE-mediated
activation. Together, these data demonstrate that the expression of
IL-33 by mast cells is dependent upon calcium activation, such as
occurs via IgE/FceRI but not via ST2.
IgE/antigen or ionomycin stimulation alters ST2
expression on mast cells
Interestingly, we also found IgE-dependent activation induced a
significant decrease in the mRNA for ST2 within BMMC
(Figure 3A) and MC/9 cells (Figure 3B). Conversely, IL-33
activation did not alter ST2 expression. In addition, the fold
induction of the co-receptor IL-1RAcP was significantly reduced
(1.0060.03 for unstimulated (n=13), verus 0.3360.03 for IgE/
DNP stimulated (n=10), p,0.05 by Students t-test). The surface
levels of ST2 were also markedly reduced by activation via IgE but
Figure 2. Mast cell expression of IL-33 requires calcium and is not induced by IL-33. 1610
6 BMMC were primed with 1 mg/ml anti-DNP IgE
(SPE-7 clone) overnight and stimulated by addition of 0.5 mg/ml DNP-HSA or 10 ng/ml of recombinant IL-33109–266. After 4 hours, the gene
expression of cytokines was determined by real-time RT-PCR in BMMC (A) and in MC/9 cells (B). IL-33 expression in response to ionomycin stimulation
was determined using BMMC (C). The expression of IL-33 was then determined in BMMC after stimulation with 0.25 mM ionomycin or IgE/antigen in
the presence or absence of 5 mM EDTA (D). *=p,0.05, **=p,0.01 by Students t-test. Data represents the mean6SEM from 6 individual wells over
two independent experiments.
doi:10.1371/journal.pone.0011944.g002
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supernatants of BMMC activated by IgE/DNP or IL-33 for
6 hours were analyzed to determine if ST2 was being shed from
mast cells. IgE/DNP activated mast cells released significantly
more sST2 into the supernatant sST2 than those from the IL-33
activated group (Figure 3D). We also saw a similar increase in
supernatant sST2 by BMMC activated by 1 mM ionomycin
(Figure 3D) and downregulation of ST2 surface expression (data
not shown).
Mast cells express IL-33 constitutively and upon
activation in vivo
To test if mast cells are a source of IL-33 in vivo, we initially
studied the levels of IL-33 within the skin of mast cell-deficient
mice (Strain WBB6F1/J-Kit
W/Kit
W-v) or littermate controls. IL-33
was significantly lower in the skin of mast cell-deficient mice
(Figure 4A) and was observed to be expressed mainly in the
epidermal and dermal regions of control mice but absent in mast-
cell deficient, as shown by immunohistochemistry (Figure 4B). To
test if IL-33 was upregulated by IgE-driven activation, we
investigated IL-33 levels in the skin using a passive cutaneous
anaphylaxis model, whereby local mast cell activation is driven by
passive IgE priming, followed by systemic antigen challenge. This
model has been shown to be strongly mast cell-dependent [40],
since mast cell-deficient mice fail to elicit responses but
reconstitution of mast cells to the skin restores responses to control
levels, as demonstrated in Figure S1. Figure 4C shows that IL-33
levels were significantly elevated at IgE-primed skin sites versus the
sham (PBS) injected skin of the same mouse. Immunohistochem-
ical staining for IL-33 showed small, compact-staining cells
throughout the epidermal/dermal zones of sham treated skin
(Figure 4D). However, IgE-treated skin demonstrated a signifi-
cantly increased number of IL-33
+ cells (7.260.36 positive cells
per high powered field (hpf) for control skin versus 10.460.78 for
IgE-treated, based on the average frequency in 10 hpf/animal,
p,0.001 by Students t-test).
IgE-mediated late phase inflammation is IL-33 and ST2
dependent
To investigate the functional effects of mast cell-derived IL-33,
we utilized neutralizing antibodies against ST2 or IL-33 and
ST2
2/2 mice in the passive cutaneous anaphylaxis model.
Figure 5A demonstrates that the initial wave of local tissue
swelling, occurring with the first few hours after antigen challenge
was unaffected by the administration of anti-IL-33 antibodies.
However, mice treated with 5 mgo fa-IL-33 showed a significantly
reduced late phase response compared to the no treatment or
isotype control groups (p,0.05 by 2-way ANOVA analysis). In
addition, administration of neutralizing a-ST2 antibodies showed
a similar diminution in the development of the late phase response
(p,0.005 for Isotype versus 5 mg a-ST2, p,0.01 for Isotype
versus 1 mg a-ST2 by 2-way ANOVA analysis) but no effect on
acute response. ST2
2/2 mice also had a similar early increase in
ear swelling within the first few hours to their ST2
+/2 littermates
but lacked the late phase inflammation (Figure 5C).
Next, we investigated the temporal expression of IL-33 after
initiation of anaphylaxis. Figure 5D demonstrates that IL-33 levels
increased during anaphylaxis but was significantly elevated only
during the late phase (12–48 hours) and not during the early phase
(1–8 hours), when compared to either IgE primed skin collected
prior to challenge (not shown) or when compared to time-matched
PBS control skin (shown). Conversely, PBS injected skin showed
Figure 3. ST2 is downregulated on mast cells after IgE-driven activation. 1610
6 BMMC (A) or MC/9 cells (B) were primed with 1 mg/ml anti-
DNP IgE (SPE-7 clone) overnight and stimulated by addition of 0.5 mg/ml DNP-HSA or 10 ng/ml of recombinant IL-33109–266. After 4 hours, the gene
expression of ST2 was determined by real-time RT-PCR. Surface expression of ST2 protein on BMMC was determined by flow cytometry after 6 hours
(C). The levels of ST2 in supernatants were analyzed by ELISA after 6 hours (D). *=p,0.05, ***=p,0.005 by Students t-test. Data in A and C
represents the mean6SEM from 3 to 6 individual wells over two independent experiments. Data in B is representative of results from three
independent experiments.
doi:10.1371/journal.pone.0011944.g003
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we determined the upregulation of IL-33 at 24 hours after antigen
challenge in W/Wv, littermate controls or in W/Wv that were
reconstituted with BMMC, as well as ST2
+/2 and ST2
2/2. IL-33
expression during anaphylaxis was significantly lower in W/Wv
mice than controls while mast cell restoration led to a significant
restoration (Figure 5E). Conversely, ST2
+/2 and ST2
2/2
demonstrated enhanced IL-33 expression to a similar degree,
despite exhibiting differences in the generation of the late-phase
inflammation (Figure 5C).
Discussion
The results of our study demonstrate that mast cells express IL-
33 and that IL-33 and ST2 are critical for the development of late-
phase inflammation occurring during anaphylaxis. BMMC have
basal expression of IL-33 and mast cell-deficient mice have
significantly lower IL-33 within their skin. Upon activation, IgE/
antigen stimulation promotes IL-33 expression via a calcium
dependent mechanism that does not occur in response to IL-33-
driven stimulation. To the best of our knowledge, these findings
are the first demonstration of a functional effect of endogenous IL-
33 in inflammation and indicate that IL-33 may be an important
mechanism through which mast cells influence the recruitment
and activation of inflammatory cells into sites of IgE-dependent
activation.
IL-33 is being increasingly recognized as an important
inflammatory cytokine. In particular, it exerts potent effects on
several cell types involved in Th2-associated inflammation,
including activation and migration of Th2 lymphocytes [4,13],
eosinophils [12,41] and basophils [14,30,41]. High expression has
also been found in Th2-associated diseases [20,21,22]. However,
much of the current functional studies on IL-33 have relied upon
administration of recombinant IL-33 and relatively little is known
Figure 4. In vivo mast cells constitutively express IL-33 and increase expression during anaphylaxis. The tissue levels of IL-33 in the skin
of wild type or mast cell deficient mice (W/Wv) were determined by ELISA (A). Additionally, frozen sections (7 mm) were stained for IL-33
immunoreactivity using biotinylated anti-IL-33 and ABC-DAB substrate and sections counterstained with hematoxylin (B). Total tissue IL-33 was
determined in IgE-primed or sham skin in passive cutaneous anaphylaxis (C) and IL-33 immunoreactivity determined, as before (D). **=p,0.01 by
Students t-test. Data in panels A and C represents the mean6SEM from 5 individual mice while panels B and D are representative of results from 4
individual mice.
doi:10.1371/journal.pone.0011944.g004
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cells express IL-33 constitutively, IL-33 was actually down-
regulated in response to pro-inflammatory stimuli [42], supporting
its suggested role as a transcriptional repressor. Our data clearly
demonstrates that mast cells express IL-33 both in vivo and in vitro
and that IL-33 is upregulated upon activation, indicating that mast
cells may be an important source of IL-33 during inflammation,
likely via its roles as a cytokine.
Mast cells are being increasingly recognized as critical cells in
regulating a broad spectrum of immune responses, both protective
and pathogenic. An important element in their abilities to
influence immunity is their capacity to release a diverse panel of
mediators, both preformed and de novo, and their ability to
respond to many stimuli. Mast cell mediators are important in
innate immunity, the transition to adaptive immunity and its
strength of response, as well as the resolution of inflammation [43].
While activated mast cells are known to promote Th2-associated
immunity [31], the critical mediators have remained elusive. IL-33
itself is amongst the spectrum of stimuli that can activate mast cells
[15,16,17,38]. Recently, using semi-quantitative approaches,
Ohno et al. proposed that BMMC can express low levels of IL-
33 mRNA in response to very high doses (30–100 ng) of IL-33
[27]. Our quantitative data shows that the expression of IL-33 by
mast cells occurs in response to IgE-mediated activation but not to
IL-33 concentrations that potently activated production of other
cytokines, suggesting that autocrine amplification is unlikey. This
is in contrast to several other cytokines, including IL-4 and IL-5,
which have been shown to promote their own expression in mast
cells [44,45]. However, antigen-driven activation via crosslinking
of IgE molecules, via FceRI [46], is the critical pathway for the
generation of immunological responses during anaphylaxis. That
different stimuli, which drive similar expression of other cytokines,
exhibit differential effects on IL-33 suggests that IL-33 might be an
important determinate of the composition and strength of the
inflammatory response.
One caveat to our in vitro studies using BMMC is that we have
failed to detect secretion of IL-33 into the supernatants. It has been
shown that BMMC represent a relatively immature phenotype
and have lower expression of several co-stimulatory receptors,
such as Toll-like receptors [47]. As such, BMMC may be
functionally refractory to release of IL-33. However, fetal skin-
derived mast cells, which express a more diverse range of Toll-like
receptors [47], also failed to release IL-33 (data not shown). The
mechanisms controlling release of IL-33 are unclear at this time.
Recently, IL-33 was suggested to be produced by macrophages
[27]. However, they also failed to detect any IL-33 in cell
supernatants, suggesting that release of IL-33 is more complicated
than a simple secretion process. Currently, only induction of
necrosis has been shown to secrete IL-33 [7], leading to the
proposal that IL-33 functions as an alarmin [48]. Determining the
mechanisms through which IL-33 becomes extracellular is likely to
be an important area for future studies on this cytokine. However,
Figure 5. IL-33/ST2 pathway is critical for the development of IgE-driven tissue inflammation during anaphylaxis. Induction of ear
swelling during passive cutaneous anaphylaxis was determined after systemic antigen challenge in mice receiving no treatment, 10 mg anti-murine
IL-33 antibody or 10 mg isotype control (A), anti-murine ST2 antibody or isotype control (B) or in ST2
2/2 or ST2
2/+ control mice (C). Data represents
the mean6SEM from 10–15 mice. The IL-33 protein levels in ear tissue from IgE injected or PBS injected sites were determined by ELISA during the
PCA time course (D) (n=3 mice per time point). Increases in IL-33 at IgE injected skin sites (determined as the delta between the PBS injected skin
from the same individual) were determined in W/Wv, reconstituted W/Wv, ST2
2/2 or relevant control strains (n=3–9 mice per group). *=p,0.05,
**=p,0.01, ***=p,0.005 by Students t-test.
doi:10.1371/journal.pone.0011944.g005
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vitro, our passive cutaneous anaphylaxis experiments demon-
strates a functional role for IL-33 and ST2 during in vivo
inflammation. One possibility is that additional signals might be
required for the secretion of IL-33 from mast cells. Mast cell-
fibroblast interactions have been shown to be required for BMMC
to secrete CCL11 (eotaxin-1), mediated via transmembrane
expression of stem cell factor (SCF) by the fibroblast [49]. Similar
cell-to-cell interactions might also be needed for mast cells to
release IL-33. Whether IL-33 associated production and release
processes are unique to mast cells or shared by other IL-33
expressing cells remains to be determined. Interestingly, we have
observed differences in the baseline levels of IL-33 within the skin
of the different strains of mice studied and yet the changes in the
levels of IL-33 induced during anaphylaxis were relatively similar.
This might suggest strain-specific influences on homeostatic IL-33
levels in cells such as endothelium that do not impact mast cell-
derived IL-33.
The late phase of anaphylaxis is characterized by a robust
recruitment of inflammatory cells but the mechanisms that
regulate this process are poorly defined. In both the skin [40]
and lung [50], antigen challenge of mice passively sensitized to
antigen-specific IgE promoted a late-phase inflammatory response.
Kaneko et al. demonstrated that the activation of mast cells
promotes late-phase anaphylactic neutrophil, but not eosinophilic,
accumulation [51] in the peritoneal cavity also. We recapitulated
in our own studies that this is highly mast cell dependent, as
previously demonstrated [40]. Both early and late-phase responses
fail to occur if mast cells lack IkB kinase (IKK) 2 [52], disrupting
IgE-mediated activation. TNF has been described as regulating
late-phase inflammation [40], perhaps via phospholipase A2
activation [53], but this effect is only partial. Our data now
demonstrates that IL-33 is a critical cytokine in regulating the late-
phase response. Despite observing some differences in the
magnitude of responses generated between experiments, in all
cases interrupting the IL-33/ST2 axis, through the use using anti-
IL-33, anti-ST2 or ST2 deficient mice, ablated this response. We
also demonstrate that deficiency in ST2 does not alter the
expression of IL-33 during anaphylaxis, suggesting ST2 is
regulating responses distal to the expression of IL-33 rather than
acting as an autocrine enhancer of mast cell activation.
Interestingly, during such late-phase responses, the cellular influx
is predominantly neutrophilic and neutrophils have been de-
scribed to not express high levels of ST2 or respond to IL-33 [54].
However, neutrophils and monocytes are actively recruited to sites
of basophil-mediated inflammation [55]. Recently, IL-33 has been
shown to enhance basophils migration in vitro in response to
CCL11 [14]. Therefore, mast cells could trigger the recruitment of
late-phase inflammation via IL-33-mediated recruitment of ST2-
expressing basophils to the site of antigen exposure. A second
possible mechanism is that IL-33 and ST2 are required to enhance
mast cell production of TNF, or other mediators, and IL-33 does
enhance mast cell production of TNF [38].
Intriguingly, a study recently showed that IL-33 is markedly
elevated in patients during anaphylactic shock, suggesting IL-33
may also play a potential role in IgE-mediated reactions in
humans also [19]. Recombinant IL-33 has been shown to enhance
mast cell responses in murine anaphylactic shock and these
authors concluded that IL-33 enhances mast cell reactivity to IgE
stimulation [19]. However, our data demonstrates that IgE-
mediated activation is associated with reduction of ST2 expression
and an increased release of sST2. Therefore, while IL-33 may be
sufficient to enhance IgE-mediated mast cell activation, we
propose that IgE-mediated activation might actually reduce the
capacity of that mast cell to subsequently respond to IL-33.
In conclusion, our data defines mast cells as a novel endogenous
source of IL-33. This occurs in response to IgE-mediated
activation but not to IL-33-driven activation and we believe that
this is likely due to the lack of calcium activation from ST2,
compared to FceRI, and we demonstrate that calcium is both
necessary and sufficient for IL-33 expression by mast cells.
Functionally, we show that IL-33 is expressed within the skin
and is upregulated during IgE-driven anaphylaxis. This expression
correlates with late-phase inflammation, rather than early phase
reactions and both IL-33 and ST2 are dispensable for the early
phase response during anaphylaxis but are required to elicit a late
phase inflammatory reaction, a mast cell-dependent process that
has been undefined to date. Mast cells are important regulators of
both innate and adaptive immunity and we postulate that mast
cell-derived IL-33 may be an important mediator in signaling the
recruitment of inflammatory cells into peripheral tissues and their
subsequent activation.
Supporting Information
Figure S1 Passive cutaneous anaphylaxis is a mast cell-
dependent model. Mast cells deficient (W/Wv) mice with or
without reconstitution of mast cells with BMMC and littermates
(WT) were investigated for their responses using the PCA model,
as described in the methods. Ear swelling was measured at the
indicated times.
Found at: doi:10.1371/journal.pone.0011944.s001 (0.14 MB TIF)
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